Stromal micropapillary pattern and CD44s expression predict worse outcome in lung adenocarcinomas with micropapillary pattern
Pathology - Research and Practice · 2023
DOI: 10.1016/j.prp.2023.154595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Yiyun Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 52 Literaturangaben. Gefördert von: West China Hospital, Sichuan University, Sichuan Province Science and Technology Support Program, Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
OBJECTIVES: This study aims to investigate the clinicopathologic characteristics of lung adenocarcinoma with micropapillary pattern (MPP) and the expression of CD44s and CD44v6 in MPP. METHODS: A total of 202 patients diagnosed with primary lung adenocarcinoma with MPP were included. We estimated the proportion of MPP in each tumor tissue and divided MPP into aerogenous micropapillary pattern (AMP) and stromal micropapillary pattern (SMP). The expression of CD44s and CD44v6 was estimated by immunohistochemical staining. Clinicopathologic data were collected from the patients' medical records. We also collected patients' follow-up data and used PFS (progression-free survival) as a survival indicator. RESULTS: Lung adenocarcinoma with MPP had a high risk of pleural invasion, lymph node metastasis, in advanced TNM stage, and a high rate of EGFR mutation. The presence of SMP indicated a higher rate of pleural invasion, lymphovascular invasion, lymph node metastasis, and a worse PFS compared with pure AMP. We found high expression of CD44s in micropapillary, especially in AMP, while the absence of CD44s expression indicated shorter survival, which was an independent unfavorable factor for PFS. CONCLUSIONS: Lung adenocarcinoma with micropapillary pattern indicated an unfavorable prognosis, which had two different pattens, AMP and SMP. SMP indicated a worse survival than AMP, and was an independent unfavorable factor for PFS. So, AMP/SMP subclassification is necessary to evaluate patient's prognosis. Furthermore, the absent expression of CD44s in micropapillary indicated shorter survival, especially in patients with EGFR mutation. Herein, CD44s may be a biological marker for micropapillary lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Pathology, West China Second University Hospital, Sichuan University, Chengdu, China.
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: 879876047@qq.com.
Förderung
- West China Hospital, Sichuan University
- Sichuan Province Science and Technology Support Program
- Science and Technology Department of Sichuan Province
- Sichuan University
Zitieren
APA
Fu, Y., Zha, J., Wu, Q., Tang, Y., Wang, W., Zhou, Q., & Jiang, L. (2023). Stromal micropapillary pattern and CD44s expression predict worse outcome in lung adenocarcinomas with micropapillary pattern. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154595
Vancouver
Fu Y, Zha J, Wu Q, Tang Y, Wang W, Zhou Q, et al. Stromal micropapillary pattern and CD44s expression predict worse outcome in lung adenocarcinomas with micropapillary pattern. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154595
BibTeX
@article{Fu2023,
author = {Fu, Yiyun and Zha, Junmei and Wu, Qian and Tang, Yuan and Wang, Weiya and Zhou, Qiao and Jiang, Lili},
title = {Stromal micropapillary pattern and CD44s expression predict worse outcome in lung adenocarcinomas with micropapillary pattern},
journal = {Pathology - Research and Practice},
year = {2023},
doi = {10.1016/j.prp.2023.154595}
}
EUVIMED